Company intelligence
GemPharmatech
Accelerating Innovation Through Genetically Engineered Mouse Models (GEMMs) and Preclinical Services
About GemPharmatech
GemPharmatech Co. Ltd., founded in 2017, is an international biotechnology enterprise specializing in the development of humanized animal models. The management and operation team has nearly 20 years of experience in gene-editing technology and animal production. GemPharmatech provides a one-stop service as model customization, breeding, phenotyping, and pharmacology for the biomedical research community. The company has developed the world's most abundant mouse strains resource to inspire scientific innovation and drive drug discovery.
Verified activity
Signals from GemPharmatech
11 published signals
Presence & Recognition
GemPharmatech participated in the final day of KSBNS 2026 at Booth 6 at the Daejeon Convention Center.
Reported by GemPharmatech
Presence & Recognition
GemPharmatech is hosting the Metabolic Disease Symposium on September 11, 2026, at the Illumina Theater in The Alexandria at Torrey Pines, San Diego, featuring discussions on incretin biology, adipose tissue, GLP-1/GIP signaling, long-acting approaches for obesity treatment, and neural mechanisms regulating feeding and body weight.
Reported by GemPharmatech
Presence & Recognition
GemPharmatech will attend the 20th Transgenic Technologies Meeting in Leiden, the Netherlands from September 15 to 18, 2026.
Reported by GemPharmatech
Products & Services
GemPharmatech released September new mouse models focused on metabolic and cardiovascular disease research, supporting studies in obesity, diabetes, dyslipidemia, and atherosclerosis.
Reported by GemPharmatech
Research & Knowledge
GemPharmatech recapped the key questions from a recent webinar on selecting the right preclinical models for GLP-1R, GIPR, and GCGR programs.
Reported by GemPharmatech
Presence & Recognition
GemPharmatech is hosting an upcoming webinar titled from Encouraging to Desiccate: Modeling Autoimmune, Genetic, and Fibrotic Kidney Disease Models on September 22, 2026.
Reported by GemPharmatech
Research & Knowledge
GemPharmatech Senior Scientific Director Dr. Shuxin Xu published a new feature in BioSpace discussing emerging obesity therapeutics, model selection in drug development, and the translation of therapies.
Reported by GemPharmatech
Presence & Recognition
GemPharmatech is hosting an annual symposium focused on metabolic disease in San Diego on September 11, 2026, featuring a program exploring obesity, insulin resistance, and cardiometabolic dysfunction.
Reported by GemPharmatech
Research & Knowledge
GemPharmatech established and developed the DIO mouse model (Strain No. 𝗧𝟬𝟬𝟮𝟬𝟰𝟬) through 60 kcal% high-fat diet feeding to evaluate weight-loss efficacy and metabolic outcomes.
Reported by GemPharmatech
Research & Knowledge
GemPharmatech humanized and gene-edited models are built to close the gap in preclinical models for the metabolic disease field, addressing efficacy plateaus and muscle loss.
Reported by Brandy Wilkinson
Presence & Recognition
GemPharmatech brought researchers to University Lab Partners in Irvine, CA for a lunch and learn focused on genetically engineered mouse models supporting translatable preclinical drug development.
Reported by GemPharmatech